Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
BioMarin Pharmaceutical raised 2025 revenue guidance on strong product sales and a $4.8B accretive Amicus acquisition, supported by FDA regulatory catalysts and an 18% stock gain over 3 weeks, validating near-term positive momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Rising Leverage ⢠Weaker Profitability ⢠Positive Free Cash Flow BMRN's strong margins and liquidity persist, but sharply higher leverage, weaker profitability, negative net cash flow, and elevated valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support testing ⢠Weak momentum Support Level: $64.40â$64.70 Resistance Level: $66.50â$67.00 BMRN remains bearish over the last month, with support at $64.40â$64.70 and resistance at $66.50â$67.00; watch for a break below support or reclaim of resistance.
Sentiment & News
Key News Insights: ⢠Alesta acquisition ⢠Royalty settlement ⢠VOXZOGO expansion BioMarin strengthened its growth outlook through the Alesta acquisition, Yuviwel royalty settlement, and positive VOXZOGO Phase 3 data supporting expansion.
AI Summary
BMRN is now a leveraged acquisition-and-execution investment rather than a pure VOXZOGO growth story, making synergy realization and cash-flow accretion from Amicus critical to justify its premium valuation as interest coverage has fallen to roughly 2x.
Description
BioMarin Pharmaceutical is a biopharmaceutical company that develops and sells therapies for rare and serious genetic and metabolic disorders, with marketed treatments across lysosomal storage disorders, phenylketonuria, Batten disease, achondroplasia and related conditions. Its late-stage pipeline includes gene therapies for hemophilia A and phenylketonuria and early-stage programs for primary hyperoxaluria, while commercial operations distribute products through specialty pharmacies, hospitals and wholesalers in the U.S., Europe, Latin America and other markets. The company maintains multiple licensing and collaboration arrangements and is headquartered in San Rafael, California, having been founded in 1996.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 22 | Dec 29 | BMRN | BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical raised 2025 revenue guidance on strong product sales and a $4.8B accretive Amicus acquisition, supported by FDA regulatory catalysts and an 18% stock gain over 3 weeks, validating near-term positive momentum. | Closed | +1.3% |